Caribou Biosciences, Inc.

NasdaqGS:CRBU Lagerbericht

Marktkapitalisierung: US$195.5m

Caribou Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Der Gewinn von Caribou Biosciences wird voraussichtlich um 21.3% pro Jahr zurückgehen, während der Jahresumsatz um 44.4% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 15.2% pro Jahr sinken. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -98.1% betragen.

Wichtige Informationen

-21.3%

Wachstumsrate der Gewinne

-15.23%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.3%
Wachstumsrate der Einnahmen44.4%
Zukünftige Eigenkapitalrendite-98.15%
Analystenabdeckung

Good

Zuletzt aktualisiert11 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • May 13

Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Nov 03

Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy

Summary Caribou Biosciences has recently reported some very exciting early data, with more in their allogeneic CAR T-cell pipeline guided by the end of the year. Encouraging myeloma data point to possible best-in-class anti-BCMA cell therapy, which could serve a very viable niche. Although there is sufficient cash to reach another data readout, I am affirming a "Hold" for CRBU here based on the need for more proving of these programs. Read the full article on Seeking Alpha
Seeking Alpha • Jan 02

Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data

Summary Caribou Biosciences, Inc. data from phase 1 ANTLER study, using CB-010 to target 2nd-line LBCLC patients and prior CD19 treated patients with partial matched HLA, expected in the 1st half of 2025. The global B-Cell Lymphoma treatment market size is expected to reach $13.14 billion by 2030. Dose-escalation data from the phase 1 CaMMouflage trial, using CB-011 for the targeting of patients with relapsed/refractory Multiple Myeloma, expected 1st half of 2025. CRBU's initiation of the phase 1 GALLOP trial, using CB-010 for the treatment of patients with lupus nephritis and extrarenal lupus, expected in the upcoming months. Read the full article on Seeking Alpha
Analyseartikel • Dec 31

Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Nov 05

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Sep 30

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Summary Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates. The FDA's Fast Track Designation for CB-010 and CB-012 supports optimism, but definitive Phase 3 data is needed to corroborate CRBU's still speculative IP. CRBU's valuation is significantly lower than its peers, but it has sufficient resources until 2H2026. Thus, I rate it a "buy" after appreciating by over 20% since my previous article. Read the full article on Seeking Alpha
Analyseartikel • Sep 06

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Jul 26

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Those holding Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares would be relieved that the share price has rebounded 39...
Seeking Alpha • Jul 03

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Summary Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgkin lymphoma. Evercore downgraded CRBU’s stock due to high COGS concerns, but its superior efficacy and safety might justify higher prices. CRBU’s CB-010 achieved a 92% ORR and favorable safety compared to competitors Yescarta and Kymriah. Despite early-stage risks, CRBU’s undervaluation and large TAM present a compelling speculative buy opportunity. Read the full article on Seeking Alpha
Analyseartikel • Jun 05

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

To the annoyance of some shareholders, Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares are down a considerable 43% in...
Seeking Alpha • Apr 18

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study indicated that CB-010 was able to generate a 90% objective response rate for patients with relapsed or refractory LBCL. Clearance was given by the FDA to initiate a phase 1 study using CB-010 for patients with lupus nephritis and extrarenal lupus; Trial initiation expected by the end of 2024. Initial dose-escalation data from the phase 1 CaMMouflage study, using CB-011 for the treatment of patients with relapsed or refractory multiple myeloma patients by end of 2024. Read the full article on Seeking Alpha
Analyseartikel • Apr 17

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders that were waiting for something to happen have been dealt a blow...
Analyseartikel • Feb 15

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Despite an already strong run, Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares have been powering on, with a gain of...
Seeking Alpha • Feb 01

Caribou Biosciences: Under The Radar With Catalysts Approaching

Summary CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names. CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data from the phase 1 ANTLER study in Q2'24. CRBU has progressed to the third dose level of CB-011 in the CaMMouflage study, and confirmed initial data are expected by year-end 2024. Read the full article on Seeking Alpha
Analyseartikel • Jan 10

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Nov 18

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are no doubt pleased to see that the share price has bounced 28...
Analyseartikel • Feb 24

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 12

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Summary Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable. If a higher dose, now ongoing, produces a durable response, this stock will likely go up. Caribou Biosciences (CRBU), founded by CRISPR pioneer Jennifer Doudna, is another CAR-T stock that has been down for months on end. Since my last coverage almost exactly a year ago, the stock is down 50%. Not a lot has happened with the company since then - which is one of the many reasons this stock is a laggard. Last year, we saw how the clinical hold on Allogene (ALLO) caused CRBU stock to falter. In October last year, the FDA placed a clinical hold on all 5 programs of Allogene following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study. Per the company: The single case involves a patient with Stage IV transformed follicular lymphoma and c-myc rearrangement whose cancer was refractory to two prior lines of immune-chemotherapy and additional radiation therapy. The patient could not receive an autologous CD19 CAR T cell therapy due to manufacturing failure associated with inadequate expansion of autologous CAR T cells. Following infusion of ALLO-501A, the patient experienced Grade 1 CRS and Grade 2 ICANS, which required a course of high dose steroid therapy. The patient subsequently developed progressive pancytopenia and a bone marrow biopsy showed aplastic anemia and the presence of ALLO-501A CAR T cells with the chromosomal abnormality. Early translational data showed that the CAR T cells expanded, peaking on Day 28, and undergoing contraction thereafter. The patient had a partial response to ALLO-501A and subsequently underwent allogeneic stem cell transplantation. Prolonged cytopenia requiring rescue stem cell transplantation has been reported in autologous CAR T therapies. This has a direct bearing on Caribou. While it uses a different gene editing technology from Allogene - chRDNA, a type of Crispr, versus the latter’s TALEN, an older but more precise technology - there are enough similarities to warrant caution. The main concern is the TRAC (T Cell Receptor Alpha Constant) edit, which occurs under both programs, and which caused the pancytopenia in the Allogene patient. Even though the tech is different, these are the same edits. In January, the FDA lifted the clinical hold for Allogene, and the collective gene editing space heaved a sigh of relief. What they said: Investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene’s manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred in the patient after the cell product was administered. It involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the T cell or B cell maturation process. I believe the FDA let it slide because there was just this one patient. Otherwise, there would have been further investigation - unrelated or not. In May, Caribou posted early data from the lowest dose cohort of lead candidate CB-010 in a phase 1 trial in penta- or more refractory NHL patients, and there was a strong drug response seen in patients, with all 5 of the 5 patients showing an overall response rate of 100%, while 80% of patients had no detectable evidence of cancer, i.e., they had a CR or complete response. The data was so good that the stock went up 30% despite some nagging safety issues - specifically, Grade 3 or 4 treatment emergent adverse events (TEAEs) developed in 5 of 6 patients.
Analyseartikel • Sep 16

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Aug 01

Caribou Biosciences: Potential To Change CAR-T Landscape

Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma are expected by the end of 2022. An IND application for the use of CB-011 for the treatment of patients with relapsed/refractory multiple myeloma is expected in the 2nd half of 2022. Caribou had $390.8 million in cash as of March 31, 2022; enough cash to fund its operations for at least the next 12 months. Caribou Biosciences, Inc. (CRBU) is a great speculative biotech play to look into. The reason why I state that is because it is developing a CRISPR-edited allogeneic CAR-T known as CB-010, which could possibly change the potential treatment landscape for CAR-T. I will go into more detail below, but the gist of the approach is to generate longer persistence compared to other CAR-Ts out there. It is advancing CB-010 in a phase 1 study treating patients with relapsed/refractory B-cell non-Hodgkin Lymphoma ((NHL)). Not only that, but there is a possibility that it could possibly advance this study quickly by having the potential to turn a phase 2 study into a registrational one. It is also advancing other candidates for hematology in that it is developing CB-011 as an allogenic CAR-T targeting BCMA for relapsed/refractory multiple myeloma ((MM)). In addition, it is developing CB-012 for patients with relapsed/refractory acute myeloid leukemia ((AML)). The downside is that both of these candidates are in the very early stages of clinical development. They are each in IND-enabling and discovery stages respectively. Not only that, but it is developing iPSC-derived CAR-NK cell therapies. The reason why is that it has observed in early testing that it may be possible to counter the immunosuppressive tumor microenvironment with the use of CB-020. Additional results from the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma are expected by the end of 2022. These are the reasons why I believe Caribou Bioscience is a great speculative biotech to look into. CB-010 For The Treatment Of Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma The main clinical program in the pipeline to go over involves the use of CB-010 for the treatment of patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. B-cell malignancies occur in B-cells (immune system cells) and most are non-Hodgkin Lymphomas. Lymphoma is cancer that develops in the lymphatic system, which is the body's fighting immune system network. The lymphatic system is composed of: Lymph Nodes, spleen, thymus gland and bone marrow area. This type of cancer affects these organs and several others. There are two main types of lymphomas that you are likely aware of, which are: Hodgkin's Lymphoma Non-Hodgkin's Lymphoma. These are the two main ones, although there are some other types. Both of these types are lymphomas that have problems with the B-cells in the body, which are responsible for fighting off infections in a person's body. The main difference is found under a microscope where each of the cells are shown to be different. There is a difference in the 5-year survival rates between Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma, which are shown directly below: Hodgkin's Lymphoma - More than 86% of patients diagnosed with this type of cancer survive 5 years or more Non-Hodgkin's Lymphoma - More than 70% of patients diagnosed with this type of cancer survive 5 years or more The main thing is that a majority of biotechs targeting the large non-Hodgkin's lymphoma market. That's because the global Non-Hodgkin's Lymphoma market is expected to reach $12.5 billion by 2027. This is a large market opportunity for any biotech. One important thing to note is that there is a specific focus for B-cells, which is the targeting of B-cells that express CD19. If you are thinking that the targeting of only CD19 expressed B-cells would limit market potential, then that would be a mistake. That's because B-cell malignancies express CD19 at normal to high levels as follows: 80% of acute lymphoblastic leukemia ((ALL)) 88% of B-cell lymphomas 100% of B-cell leukemia. As you can see, the targeting of CD19 specifically won't hinder the possible market opportunity. It dosed the first patient for the phase 1 ANTLER study back in July of 2021. This early-stage study intends to recruit about 50 patients and then evaluate them for safety and efficacy of CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. The primary endpoint for this trial is objective response rate ((ORR)). Thus far, I believe that this biotech is on the right track. Why do I state that? It is because it had seen excellent data from several patients that were only given one starting dose of CB-010 which is 40x106 CAR-T cells. It is important to note that this is dose level 1, because it is now in the process of dose level 2. Speaking of dose level 1 for this phase 1 ANTLER study, as I stated before, it was able to obtain impressive results just with one dose given at this level. It was revealed that there was a 100% complete response ((CR)) rate observed as best response as of the cutoff date of May 13, 2022. At 6 months following a single dose noted above, the CR was 40% (2 of 5 patients). This is not bad for patients only being given a single dose of therapy. Another item to note which I think is great is that 1 patient evaluated after the May 13, 2022, cutoff date maintained CR to 12 months. In addition, these were patients who had relapsed with prior treatments. They relapsed after a median of 3 prior therapies, ranging from 2 to 8 therapies. They were very sick patients to begin with. What comes next? Well, there is potential to improve efficacy. This can be done if dose level 2, which is 80x106 CAR-T cells, can achieve an improvement in terms of objective response rate over an extended period of time. A risk to be aware of is that dose level 1 consisted of adverse events which were consistent with other allogeneic and autologous CAR-Ts. This means that if adverse events are even worse with the next dose, there is a possibility that Caribou will have to stick with the current dose. I don't view this as a bad thing, being that one dose of CB-010 at dose level 1 is already strong as it is. Investors/traders wont' have to wait that long to see data from dose level 2. Additional results from the phase 1 ANTLER study are expected at the end of 2022. Improvement Of CAR-Ts Through PD-1 Knockout Why does this biotech hold the potential to change the landscape of CAR-T? The reason all has to do with the technology it has. That is, developing a CRISPR-edited allogeneic CAR-T, which can possibly improve persistence in the patient. More specifically, it is the first allogeneic CAR-T cell therapy to include edits to achieve this function. There are three edits which are done as follows: Inserting CD-19 specific CAR into the T-cell genome Remove TRAC gene in place to remove T-cell receptor Knockout gene encoding PD-1. The last bullet point above of knocking out PD-1 is especially important. It believes that knocking out PD-1 may lead to persistence of the CAR-T cell itself against the tumor. Other improvements with such an edit could be the ability to reduce CB-010 exhaustion. This makes a lot of sense, because while CAR-Ts are highly effective treatments, one major issue a lot of them lack is the ability to persist for an extended period of time. The first CAR-T CB-010 may possibly be advanced into the clinic quickly. Caribou believes that there is a chance for an eventual phase 2 study to be a registrational one. If the FDA sees compelling data in phase 1, then it's possible that it may allow a phase 2 study to become a registrational one. This all depends on unmet medical need, how good the data is and rules established by the agency at the time of a meeting. Additional CAR-Ts With Different Edits And Approaches As I noted above, CB-010 has 3 CRISPR edits in place to be altered. Well, what I think is interesting about Caribou is the ability to go a different route with its other allogenic CAR-Ts. What do I mean by that? Well, looking at the very next product in the pipeline CB-011, it incorporates 4 edits. The main edit to make note of is the ability to present a minor HLA class I antigen, which is responsible for removing T- and NK-mediated rejection of the CAR-T cell therapy by the patient's very own immune system. In essence, CB-011 incorporates what is known as immune cloaking to achieve this function. The other CAR-T in the pipeline known as CB-012 is being developed to target CLL-1 ((CD371)), which is expressed on Acute Myeloid Leukemia ((AML)) tumor cells and not on normal hematopoietic stem cells. There is a catalyst with respect to this clinical candidate. It is said that an IND application for the use of CB-011 for the treatment of patients with relapsed/refractory multiple myeloma ((MM)) is expected in the 2nd half of 2022.

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CRBU - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202835-182N/AN/A4
12/31/202730-157N/AN/A5
12/31/202626-125N/AN/A6
3/31/202611-133-102-101N/A
12/31/202511-148-112-111N/A
9/30/20259-157-128-126N/A
6/30/20259-164-136-133N/A
3/31/202510-148-142-138N/A
12/31/202410-149-145-138N/A
9/30/202411-148-132-124N/A
6/30/202433-123-133-120N/A
3/31/202433-115-115-103N/A
12/31/202334-102-105-93N/A
9/30/202335-95-108-97N/A
6/30/202314-111-99-91N/A
3/31/202315-108-106-97N/A
12/31/202214-99-98-91N/A
9/30/202213-91-93-87N/A
6/30/202213-85-86-80N/A
3/31/202211-73-78-75N/A
12/31/202110-67-36-33N/A
9/30/20218-63-22-19N/A
6/30/20215-50-14-13N/A
3/31/202112-38-4-4N/A
12/31/202012-34-35-33N/A
12/31/20196-23N/A-32N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRBU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CRBU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CRBU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CRBUDie Einnahmen des Unternehmens (44.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: CRBUDie Einnahmen des Unternehmens (44.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CRBU wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 18:29
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Caribou Biosciences, Inc. wird von 10 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Alec StranahanBofA Global Research
Leah Rush CannBrookline Capital Markets
Yigal NochomovitzCitigroup Inc